[ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 10
First page : ( 4529) Last page : ( 4534)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00798.2

Synthesis of Novel molecular hybrid 3-(4,5-dihydro-1H-pyrazol-3-yl)-4-hydroxy-2H-chromen-2-one derivatives and In Vitro α-glucosidase and α-amylase inhibitory activity

Telvekar Vikas N.1, Mundlod Krishna N.2,*, Jadhav Ghanshyam B.2, Hatvate Navnath T.1, Ghodse Shrikant M.1

1Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai-400019, (Maharashtra), India

2Department of Pharmaceutical Chemistry, MVP Samaj’s College of Pharmacy, Nashik - 422002Dist - Nashik, (Maharashtra), India

*Corresponding Author E-mail: mundlodk@gmail.com

Online published on 28 October, 2020.


A novel series of 3-(4,5-dihydro-1H-pyrazol-3-yl)-4-hydroxy-2H-chromen-2-one derivatives was designed based on molecular hybridization technique. A series of 3-(1-benzoyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-4-hydroxy-2H-chromen-2-one derivatives (6a-6p) that incorporate a variety of substituents at the 2 and 4 position of the benzyl moiety have been synthesized. These compounds were evaluated for their antidiabetic activity against α-glucosidase and α-amylase. The biological screening indicates that these hybrid derivatives exhibited promising IC50 values in the range of 91.24μM -261.82μM and 85.03μM -237.78μM respectively. Two analogs, 6j and 6m have shown most potential activity against both α-glucosidase and α-amylase were identified as potent antidiabetic agents.



2H-chromen-2-one, 4-Hydroxycoumarin, α-glucosidase, α-amylase, Antidiabetic agents, Hypoglycemic agent.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
763,344,126 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.